RCT | Dabrafenib and Trametinib vs. Nivolumab and Ipilimumab for patients with advanced BRAF-mutant melanoma.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 – Journal of Clinical Oncology

News Release: Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy – Georgetown University Medical Center

Commentary: Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma – HealthDay